Juno Therapeutics Company Profile (NASDAQ:JUNO)

Analyst Ratings

Consensus Ratings for Juno Therapeutics (NASDAQ:JUNO) (?)
Ratings Breakdown: 3 Hold Rating(s), 10 Buy Rating(s)
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $54.50 (87.09% upside)

Analysts' Ratings History for Juno Therapeutics (NASDAQ:JUNO)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Maxim GroupReiterated RatingBuy$80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2016Leerink SwannReiterated RatingBuy$86.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/9/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2016Cowen and CompanyReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/8/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$63.00 -> $39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016Barclays PLCInitiated CoverageEqual Weight$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Raymond James Financial Inc.Initiated CoverageOutperform$52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016SunTrust Banks Inc.Reiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyBoost Price Target$48.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2016Deutsche Bank AGInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$50.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2016GuggenheimUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015Northland SecuritiesInitiated CoverageOutperform$64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Juno Therapeutics (NASDAQ:JUNO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/9/2016Q116($0.52)($0.78)$4.83 million$9.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.47)($0.53)$4.79 million$4.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.41)($0.53)$6.41 million$1.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.37)($0.35)$2.03 million$12.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.35)($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015Q414($0.33)($1.61)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Juno Therapeutics (NASDAQ:JUNO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.67)($0.67)($0.67)
Q2 20161($0.47)($0.47)($0.47)
Q3 20161($0.52)($0.52)($0.52)
Q4 20161($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Juno Therapeutics (NASDAQ:JUNO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Juno Therapeutics (NASDAQ:JUNO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016Richard KlausnerDirectorSell12,000$40.71$488,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2016Hyam LevitskyEVPSell12,418$42.77$531,117.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Steve HarrCFOSell30,000$43.32$1,299,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016Hans Edgar BishopCEOSell90,750$46.42$4,212,615.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Bernard J CassidyGeneral CounselSell3,116$39.03$121,617.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Bernard J CassidyGeneral CounselSell3,200$43.12$137,984.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Richard KlausnerDirectorSell12,000$42.90$514,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016Anthony B EvninDirectorBuy8,000$36.58$292,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Bernard J CassidyGeneral CounselSell3,200$38.18$122,176.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Steve HarrInsiderSell5,000$45.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Richard KlausnerDirectorSell24,000$40.42$970,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Douglas K BrattonMajor ShareholderSell8,600,000$39.00$335,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Steve HarrInsiderSell30,000$37.58$1,127,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016Bernard J. CassidyGeneral CounselSell3,200$34.50$110,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Bernard J. CassidyGeneral CounselSell3,200$33.55$107,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015Bernard J. CassidyGeneral CounselSell3,200$45.39$145,248.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015Steve HarrinsiderSell35,000$46.43$1,625,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Bernard J. CassidyGeneral CounselSell3,200$52.97$169,504.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Richard KlausnerDirectorSell12,000$49.51$594,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Bernard J. CassidyGeneral CounselSell3,200$49.85$159,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Richard KlausnerDirectorSell8,000$50.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Richard KlausnerDirectorSell16,000$50.00$800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Bernard J. CassidyGeneral CounselSell11,850$42.50$503,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Bernard J. CassidyGeneral CounselSell11,850$40.15$475,777.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Bernard J CassidyGeneral CounselSell11,850$50.55$599,017.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Richard KlausnerDirectorSell8,000$53.34$426,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2015Douglas K BrattonMajor ShareholderSell40,000$54.75$2,190,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Anthony B EvninDirectorSell583,333$48.11$28,064,150.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Bernard J CassidyGeneral CounselSell11,850$51.34$608,379.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015Douglas K BrattonMajor ShareholderSell270,000$51.13$13,805,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Richard KlausnerDirectorSell8,000$52.29$418,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Anthony B EvninDirectorSell583,333$52.88$30,846,649.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Douglas K BrattonMajor ShareholderBuy625,000$24.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Hal BarronDirectorBuy100,000$24.00$2,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Douglas K BrattonMajor ShareholderBuy625,000$25.00$15,625,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Juno Therapeutics (NASDAQ:JUNO)
DateHeadline
07/23/16 04:30 PMNotable Analysts Recommendation to Monitor: Gilead Sciences, Inc ... - Street Updates
07/23/16 08:47 AMJUNO THERAPEUTICS INC
07/22/16 04:45 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Juno Therapeutics, …
07/22/16 04:09 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Juno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - JUNO - [PR Newswire] - NEW YORK, July 22, 2016 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ: JUNO) ...
07/21/16 04:57 PMAnalysts Rating Overview: Astrazeneca PLC (NYSE:AZN) , Juno Therapeutics, Inc. (NASDAQ:JUNO) - Street Updates
07/21/16 04:57 PMScott + Scott, LLP Notifies Investors of Juno Therapeutics, Inc. (Nasdaq: JUNO) Securities Lawsuit, Encourages ... - GlobeNewswire (press release)
07/21/16 01:31 PMSuper Bowl Champ Joe Theismann Talks Markets -
07/21/16 12:03 PMSHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Juno Therapeutics Inc. ("Juno" or the "Company") (NASDAQ: JUNO) ...
07/21/16 10:04 AMScott + Scott, LLP Notifies Investors of Juno Therapeutics, Inc. (Nasdaq: JUNO) Securities Lawsuit, Encourages Investors With Losses to Contact Firm - [GlobeNewswire] - NEW YORK, July 21, 2016-- Scott+ Scott, Attorneys at Law, LLP, a global investor rights law firm, notifies investors that a securities lawsuit has been filed on behalf of investors in Juno Therapeutics, ...
07/21/16 09:25 AMINVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action against Juno Therapeutics, Inc. (JUNO) & Lead Plaintiff Deadline: September 12, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 21, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court Western District of Washington ...
07/20/16 09:15 PMCrisis of the Week: Patient Deaths Flummox Juno Therapeutics
07/20/16 02:53 PMNotable Buzzers: Cerulean Pharma Inc. (NASDAQ:CERU) , Juno Therapeutics, Inc. (NASDAQ:JUNO) - Street Updates
07/20/16 02:53 PMINVESTOR ALERT: Hagens Berman Alerts Juno Therapeutics Inc ... - GlobeNewswire (press release)
07/20/16 10:14 AMIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that a class action lawsuit has been filed against Juno Therapeutics Inc. . Investors who purchased or otherwise acquired shares between June 4, 2016 and July 7, 2016 inclusive , are encouraged to contact the Firm prior to the September 12, 2016 lead plaintiff motion deadline.
07/20/16 09:30 AMThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Juno Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm - [Business Wire] - Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Juno Therapeutics, Inc. securities between June 4, 2016 and July 7, 2016, inclusive .
07/20/16 08:30 AMINVESTOR ALERT: Hagens Berman Alerts Juno Therapeutics Inc. (NASDAQ: JUNO) Investors Insider Selling Securities Class Action and September 12, 2016 Lead Plaintiff Deadline - [GlobeNewswire] - SAN FRANCISCO, July 20, 2016-- Hagens Berman Sobol Shapiro LLP alerts investors in Juno Therapeutics Inc. that a securities class action is pending in the United States District Court for the Western District ...
07/20/16 07:48 AMHC Stocks Newsbeat: Edwards Lifesciences Corp (NYSE:EW), Juno Therapeutics Inc (NASDAQ:JUNO) - share market updates (press release)
07/20/16 07:48 AMCrisis of the Week: Patient Deaths Flummox Juno Therapeutics - Wall Street Journal (blog)
07/19/16 04:54 PMNext Weeks Broker Price Targets For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
07/19/16 04:54 PMCommit To Purchase Juno Therapeutics At $20, Earn 17.5% Using Options
07/19/16 04:54 PMMaxim Group Reiterates "Buy" Rating for Juno Therapeutics Inc (JUNO)
07/19/16 03:38 PMGE May Be Poised For Breakout If Q2 Earnings Can Top Consensus -
07/19/16 12:02 PMINVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - [Business Wire] - Goldberg Law PC announces that a class action lawsuit has been filed against Juno Therapeutics Inc. . Investors who purchased or otherwise acquired shares between June 4, 2016 and July 7, 2016 are encouraged to contact the firm in advance of the September 12, 2016 lead plaintiff motion deadline.
07/19/16 09:20 AMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Juno Therapeutics, Inc. (JUNO) and Lead Plaintiff Deadline: September 12, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 19, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court Western District of Washington ...
07/19/16 08:05 AMSHAREHOLDER ALERT: Class Action Lawsuit Filed Against Juno Therapeutics, Inc. - JUNO - [Accesswire] - RADNOR, PA / ACCESSWIRE / July 19, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Juno Therapeutics, Inc. (NASDAQ: JUNO) ("Juno" or the "Company") shareholders that ...
07/18/16 09:07 PMJUNO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Juno Therapeutics, Inc. - JUNO - [GlobeNewswire] - NEW ORLEANS, July 18, 2016-- Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 12, 2016 to file lead ...
07/18/16 04:59 PMHot Biotech Stocks Recap: Ariad Pharmaceuticals (NASDAQ:ARIA), Juno Therapeutics (NASDAQ:JUNO) - The Voice Registrar
07/18/16 04:59 PMLeerink Weighs In on Juno Therapeutics Inc (JUNO) Following Acquisition of RedoxTherapies - Smarter Analyst
07/18/16 04:59 PMAnalyst Recommended Stock: Juno Therapeutics Inc. (NASDAQ:JUNO) - News Oracle
07/18/16 02:39 PMIMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Juno Therapeutics, Inc. To Contact Brower Piven Before - [GlobeNewswire] - STEVENSON, Md., July 18, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ...
07/18/16 12:34 PMIMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that a class action lawsuit has been filed against Juno Therapeutics Inc. . Investors who purchased or otherwise acquired shares between June 4, 2016 and July 7, 2016 inclusive , are encouraged to contact the Firm prior to the September 12, 2016 lead plaintiff motion deadline.
07/18/16 11:49 AMJUNO INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016 - [GlobeNewswire] - NEW YORK, July 18, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors ...
07/18/16 10:03 AMLawsuit for Investors in Shares of Juno Therapeutics Inc (NASDAQ:JUNO) in Effort to Recover Losses Filed
07/17/16 12:59 PMForget the Me-Too Cancer Drugs -- These Breakthroughs Are Where You Want to Invest -
07/16/16 04:29 PMJuno Therapeutics, Inc. and Its CEO Sued for Securities Fraud by Block & Leviton LLP - GlobeNewswire (press release)
07/16/16 08:10 AMFDA stops Juno's cancer drug trials after 3 patients die
07/16/16 08:10 AMShareholder Class Action Filed Against Juno Therapeutics, Inc. - Juno
07/15/16 07:15 PMJuno Therapeutics, Inc. and Its CEO Sued for Securities Fraud by Block & Leviton LLP - [GlobeNewswire] - BOSTON, July 15, 2016-- Juno Therapeutics, Inc. and its chief executive officer, Hans E. Bishop, were named as defendants in a lawsuit filed earlier this week by Block & Leviton LLP and Tousley Brain Stephens ...
07/15/16 03:51 PMJuno Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/15/16 03:51 PMShareholder Class Action Filed Against Juno Therapeutics, Inc. - Juno - PR Newswire (press release)
07/15/16 03:47 PMSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Juno Therapeutics, Inc. and Certain Officers – JUNO - [GlobeNewswire] - NEW YORK, July 15, 2016-- Pomerantz LLP announces that a class action lawsuit has been filed against Juno Therapeutics, Inc. and certain of its officers. The class action, filed in United States District ...
07/15/16 02:44 PMRobbins Arroyo LLP: Juno Therapeutics, Inc. (JUNO) Misled Shareholders According to a Recently Filed Class Action - [Business Wire] - Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Juno Therapeutics, Inc. in the U.S. District Court for the Western District of Washington at Seattle.
07/15/16 02:07 PMSHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Juno Therapeutics, Inc. - [GlobeNewswire] - WILMINGTON, Del., July 15, 2016-- Rigrodsky & Long, P.A.:. Do you, or did you, own shares of Juno Therapeutics, Inc.? Did you purchase your shares between June 4, 2016 and July 7, 2016, inclusive?
07/15/16 11:43 AMSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Juno Therapeutics Inc. And Reminds Investors With Losses To Contact The Firm - [Business Wire] - Lundin Law PC announces a class action lawsuit has been filed against Juno Therapeutics Inc. concerning possible violations of federal securities laws between June 4, 2016 and July 7, 2016 .
07/15/16 08:46 AMStock to keep an eye on: Juno Therapeutics Inc. (NASDAQ:JUNO) - News Oracle
07/15/16 08:46 AMWhy Wynn Resorts, Limited (WYNN), Juno Therapeutics Inc (JUNO) and Brocade Communications Systems, Inc ... - Investorplace.com
07/15/16 08:46 AMStocks inside Analysts Spotlight: Juno Therapeutics, Inc. (NASDAQ:JUNO) , ARIAD Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/15/16 08:46 AMINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Juno Therapeutics Inc. of a Class Action Lawsuit ... - PR Newswire (press release)
07/15/16 08:46 AMStock Update (NASDAQ:JUNO): Juno Therapeutics Inc Adds Adenosine Receptor Antagonist Through Acquisition of ... - Smarter Analyst
07/15/16 07:40 AMWhy Juno Therapeutics (JUNO) Could Be Positioned for a Slump -

Social

About Juno Therapeutics

Juno Therapeutics logoJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno's product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Juno's other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: JUNO
  • CUSIP:
Key Metrics:
  • Previous Close: $29.13
  • 50 Day Moving Average: $38.00
  • 200 Day Moving Average: $37.51
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $2.95B
  • Beta: 2.8
  • Current Year EPS Consensus Estimate: $-2.28 EPS
  • Next Year EPS Consensus Estimate: $-2.17 EPS
Additional Links:
Juno Therapeutics (NASDAQ:JUNO) Chart for Saturday, July, 23, 2016